(19)

(11)

EP 3 349 756 A1

(12)

(43) Date of publication: 25.07.2018 Bulletin 2018/30 (21) Application number: 16847459.1 (22) Date of filing: 16.09.2016

(51) International Patent Classification (IPC):  A61K 31/485(2006.01) A61K 31/451(2006.01) A61K 31/4468(2006.01) (86) International application number: PCT/US2016/052280 (87) International publication number: WO 2017/049181 (23.03.2017 Gazette 2017/12)

(84) Designated Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR Designated Extension States: BA ME Designated Validation States: MA MD (30) Priority: 17.09.2015 US 201562219955 P 04.01.2016 US 201662274536 P (71) Applicants: Adapt Pharma Limited Dublin 2 (IE) Opiant Pharmaceuticals Santa Monica, California 90401 (US)

(72) Inventors: KEEGAN, Fintan Dublin 2 (IE) BELL, Robert Gerard Clearwater, Florida 33765 (US) CRYSTAL, Roger Santa Monica, California 90402 (US) WEISS, Michael Brenner New York, New York 10128 (US) (74) Representative: Haseltine Lake LLP  Redcliff Quay 120 Redcliff Street Bristol BS1 6HU Bristol BS1 6HU (GB)